|  | Number of patients (percentage) |
---|---|---|
Total number of patients | Â | 73 |
Age at diagnosis (years) | ≤50 >50 | 34 (46.6) 39 (53.4) |
 | Range | 29 to 77 |
Tumour size (cm) | <2.0 ≥2.0 | 20 (27.4) 53 (72.6) |
Number of positive lymph nodes | 0 1–3 >3 | 21 (28.8) 20 (27.4) 32 (43.8) |
Histological grade | 1 2 3 | 12 (16.4) 42 (57.5) 19 (26.1) |
Adjuvant therapy | None Endocrine therapy Chemotherapy Combined | 5 (6.9) 32 (43.8) 2 (2.7) 34 (46.6) |
Disease-free interval (months) | Mean ± SD Median | 39.8 ± 25.7 38 |
 | Range | 2 to 123 |
First-line endocrine therapy for metastatic breast cancer | Tamoxifen Aromatase inhibitors LHRH agonist LHRH agonist + tamoxifen Fulvestrant | 56 (76.7) 9 (12.3) 3 (4.1) 4 (5.5) 1 (1.4) |